Related Experiment Video
Updated: Aug 11, 2026

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
Drug delivery from ocular implants
Tsutomu Yasukawa1, Yuichiro Ogura, Hideya Kimura
1Department of Ophthalmology, Nagoya City University Medical School, Aichi 467-8601, Japan. yasukawa@kuhp.kyoto-u.ac.jp
Abstract:
Developing an intraocular drug delivery system (DDS) is urgently needed because most vitreoretinal diseases are refractory to conventional pharmacological approaches; eye drops and systemically administered drugs cannot deliver therapeutic drug concentrations into vitreoretinal tissue. Intraocular DDSs address this problem. Intraocular sustained-drug release via implantable devices or injectable microparticles has been investigated to treat vitreoretinal diseases. A nonbiodegradable implant was first used in 1996 for cytomegalovirus retinitis secondary to the acquired immunodeficiency syndrome. Biodegradable implants, composed of hydrophilic or hydrophobic polymers, in the shape of rods, plugs, discs or sheets have been investigated. An injectable rod is presently being assessed in a Phase III trial to treat macular oedema secondary to diabetic retinopathy or branch-retinal vein occlusion. Intraocular DDSs using a biodegradable implant may soon be successfully used to treat serious intraocular disorders.
Related Concept Videos
Ophthalmic Drug Delivery Systems
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Intrauterine Drug Delivery Systems
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Oral Drug Delivery Systems: Delayed-Release Systems
Modified-Release Drug Delivery Systems: Stimuli-Activated

